Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Hypoxia 4Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Immune System Diseases 1Head and Neck Neoplasms 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × pimonidazole × Clear all
NCT03718650 2021-02-08

Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01248637 2018-07-30

Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole

University Health Network, Toronto

Completed
200 enrolled
Gastrointestinal

Hypoxia, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡